BIOMAT Database Logo BIOMAT Database Logo

[Treatment of Parkinson disease with L-DOPA and dopamine agonists]. 1994

N Ogawa

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D018491 Dopamine Agonists Drugs that bind to and activate dopamine receptors. Dopamine Receptor Agonists,Dopaminergic Agonists,Agonists, Dopamine Receptor,Agonists, Dopaminergic,Dopamine Agonist,Dopamine Receptor Agonist,Dopaminergic Agonist,Receptor Agonists, Dopamine,Agonist, Dopamine,Agonist, Dopamine Receptor,Agonist, Dopaminergic,Agonists, Dopamine,Receptor Agonist, Dopamine

Related Publications

N Ogawa
[Parkinson disease--problems in long-term treatment. Dopamine agonists optimize L-dopa therapy].
February 1997, Fortschritte der Medizin,
N Ogawa
[Chemotherapy of Parkinson disease with agents other than L-DOPA or dopamine agonists].
April 1994, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
N Ogawa
Initial treatment of Parkinson disease: levodopa or dopamine agonists.
December 2004, Archives of neurology,
N Ogawa
[Current treatment of Parkinson syndrome with L-dopa].
May 1972, Polski tygodnik lekarski (Warsaw, Poland : 1960),
N Ogawa
Dopamine agonists for early Parkinson disease.
July 2009, American family physician,
N Ogawa
[Dopamine agonists situation in Parkinson disease].
January 2001, Revista de neurologia,
N Ogawa
Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists.
November 2023, Biomolecules,
N Ogawa
Hiccups associated with dopamine agonists in Parkinson disease.
March 2006, Neurology,
N Ogawa
[Parkinson-therapy with dopamine agonists].
June 1996, Der Nervenarzt,
N Ogawa
[Parkinson therapy with L-dopa].
January 1971, Deutsche medizinische Wochenschrift (1946),
Copied contents to your clipboard!